NeOnc CEO Amir Heshmatpour has demonstrated strong confidence by purchasing over $500,000 of NeOnc shares in recent weeks, bringing his total open-market purchases to nearly $1 million over the past year. Such accumulation ahead of a major clinical catalyst is rare in biotech, signaling management’s conviction in upcoming trial results and likely influencing investor sentiment.

NEO100, currently in a fully enrolled Phase 2a trial, is engineered to overcome the blood-brain barrier challenge in treating glioblastoma. If interim data confirm its ability to deliver therapeutic agents into the brain effectively, NeOnc could validate a platform technology that unlocks treatments for a broad range of central nervous system disorders, from metastatic cancers to neurodegenerative diseases.